27%

IMPROVEMENT
AT WEEK 24

with DUPIXENT vs 1% improvement with
placebo in SINUS-52 (P<0.0001)2,a

38%

CONTINUED IMPROVEMENT
AT WEEK 52

with DUPIXENT vs 2% worsening with
placebo in SINUS-522,b

(analysis of change at Week 52 was not multiplicity controlled; result is descriptive)

aWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) vs placebo + INCS (n=153): -5.13 (95% CI: -5.80, -4.46) (-5.2 from a baseline score of 18.12 vs -0.09 from a baseline score of 17.65, respectively).2

b Week 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -6.94 (95% CI: -7.87, 6.01) (-6.83 from a baseline score of 18.42 vs 0.11 from a baseline score of 17.65, respectively).2

DUPIXENT is the only approved
biologic in CRSwNP that evaluated
changes in LMK‑CT scores in
pivotal trials (SINUS-24 and
SINUS-52)1

SEE THE SCAN FROM A REAL DUPIXENT PATIENT
Click and drag
to see results

CT scan of patient from clinical trial. Individual results may vary.

DUPIXENT demonstrated statistically significant reductions in
opacification across all individual sinuses at Week 242

Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.1

CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

see nasal polyp score

BACK TO SINUS SURGERY +
STEROID USE RESULTS

Explore the Safety Data and Study Designs

View Safety Data SEE THE FULL STUDY DESIGNS

Dosage and
Administration
See the recommended dosing and administration options for patients on DUPIXENT.
Explore ADMINISTRATION Options